Lipocine (LPCN) Enterprise Value (2011 - 2025)
Lipocine's (LPCN) quarterly Enterprise Value came in at -$23.9 million in Q4 2025, up 35.4% YoY from -$17.7 million in Q4 2024, and up 9.07% on a QoQ basis from -$26.3 million in Q3 2025.
Lipocine (LPCN) Enterprise Value (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Enterprise Value data on file, last reported at -$23.9 million in Q4 2025.
- Quarterly Enterprise Value rose 35.4% year-over-year to -$23.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$23.9 million (up 35.4% YoY) and the FY2025 annual result came in at -$23.9 million, up 35.4% from the prior year.
- Enterprise Value climbed to -$23.9 million in Q4 2025, from -$26.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$23.9 million in Q4 2025 to a low of -$87.4 million in Q4 2021.
- A 5-year average of -$50.9 million and a median of -$45.7 million in 2021 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value sank 345.38% — and 2023, when it surged 36.18%.
- Tracing LPCN's Enterprise Value over 5 years: stood at -$87.4 million in 2021, then climbed by 29.72% to -$61.5 million in 2022, then surged by 36.18% to -$39.2 million in 2023, then rose by 5.64% to -$37.0 million in 2024, then jumped by 35.4% to -$23.9 million in 2025.
- The last three Enterprise Value figures came in at -$23.9 million (Q4 2025), -$26.3 million (Q3 2025), and -$29.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 2.12 Bn |
| 10 | Lipocine | 11.42 Mn | -12.49 Mn | - | -23.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.91 Mn |
| Sep 30, 2025 | -26.29 Mn |
| Jun 30, 2025 | -29.54 Mn |
| Mar 31, 2025 | -36.07 Mn |
| Dec 31, 2024 | -37.01 Mn |
| Sep 30, 2024 | -35.90 Mn |
| Jun 30, 2024 | -39.74 Mn |
| Mar 31, 2024 | -46.05 Mn |
| Dec 31, 2023 | -39.22 Mn |
| Sep 30, 2023 | -43.75 Mn |
| Jun 30, 2023 | -46.45 Mn |
| Mar 31, 2023 | -52.55 Mn |
| Dec 31, 2022 | -61.46 Mn |
| Sep 30, 2022 | -65.58 Mn |
| Jun 30, 2022 | -69.58 Mn |
| Mar 31, 2022 | -77.47 Mn |
| Dec 31, 2021 | -87.45 Mn |
| Sep 30, 2021 | -72.37 Mn |
| Jun 30, 2021 | -81.52 Mn |
| Mar 31, 2021 | -45.35 Mn |